Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Infosys Stock Today: INFY Rises as Accenture Lifts IT Sentiment—Analyst Targets, Q3 Earnings Date, and What Could Move Shares Next

Infosys Stock Today: INFY Rises as Accenture Lifts IT Sentiment—Analyst Targets, Q3 Earnings Date, and What Could Move Shares Next

Infosys Limited (NSE: INFY, BSE: 500209; NYSE: INFY) ended Friday, December 19, 2025 with a modest but telling uptick in India—up 0.81% to ₹1,639.60—as global IT services sentiment improved after Accenture’s latest numbers signaled steadier demand than many investors feared heading into 2026. MarketWatch+1 The move wasn’t just about a single day’s price action. Markets are increasingly treating the next few weeks as a “catalyst corridor” for Infosys stock: a fresh read on enterprise tech budgets, the firm’s ability to convert large deal wins into revenue, and—crucially—whether management tightens or lifts its growth outlook again when it reports its next
Bloom Energy Stock (NYSE: BE) Rebounds on Dec. 19, 2025: Latest News, Analyst Forecasts, and What’s Next for the AI Data-Center Fuel-Cell Play

Bloom Energy Stock (NYSE: BE) Rebounds on Dec. 19, 2025: Latest News, Analyst Forecasts, and What’s Next for the AI Data-Center Fuel-Cell Play

Bloom Energy Corporation stock is back in motion on December 19, 2025, after a week that reminded investors of an eternal market truth: the hottest narratives also come with the sharpest whiplash. As of 14:39 UTC (9:39 a.m. ET), BE stock was trading at $86.06, up $5.85 (+7.29%) on the day, after opening around $81.41 and touching an intraday high of $86.06. That bounce matters because it follows a dramatic string of moves earlier in December—$119.18 on Dec. 5 down to $76.97 on Dec. 17, then a rebound to $80.21 on Dec. 18—a rollercoaster that has turned Bloom Energy stock
19 December 2025
Carnival Corporation & plc Stock (CCL): Record 2025 Results, Dividend Reinstated, and 2026 Outlook — What Changed on Dec. 19, 2025

Carnival Corporation & plc Stock (CCL): Record 2025 Results, Dividend Reinstated, and 2026 Outlook — What Changed on Dec. 19, 2025

Carnival Corporation & plc (NYSE: CCL; NYSE: CUK; LSE: CCL) put a lot of catalysts on the table on December 19, 2025: record full-year performance, a return of the dividend for the first time since the pandemic-era suspension, upbeat 2026 earnings expectations, and a proposal to simplify its dual-listed corporate structure. The market noticed. As of 14:38 UTC on Friday, Dec. 19, shares of Carnival (CCL) traded around $29.34, up roughly $1.00 from the prior close (about +3.5%). Below is a detailed rundown of the news, forecasts, and analyst narratives circulating on 19.12.2025—and what investors are likely to focus on
CoreWeave Stock (CRWV) Jumps on DOE “Genesis Mission” News and Citi Buy Call: Today’s Forecasts, Catalysts, and Key Risks (Dec. 19, 2025)

CoreWeave Stock (CRWV) Jumps on DOE “Genesis Mission” News and Citi Buy Call: Today’s Forecasts, Catalysts, and Key Risks (Dec. 19, 2025)

Dec. 19, 2025 — CoreWeave, Inc. (Nasdaq: CRWV) is back in the spotlight after a sharp rebound in its share price on Friday, powered by a double dose of momentum: fresh headlines tied to a U.S. government initiative and a renewed (if clearly risk-labeled) vote of confidence from Wall Street. CoreWeave shares were trading around $74.68 in mid-morning U.S. trading (9:39 a.m. ET), up roughly 10% on the day, after closing at about $67.61 on Dec. 18, according to delayed pricing data. FinancialContent In premarket action, a Reuters item carried by TradingView reported the stock was up about 5.9% to
19 December 2025
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1 The acquisition is the latest example of a larger biotech company using M&A to secure near‑term revenue and strengthen long‑term growth, particularly in rare disease categories where commercialization requires specialized manufacturing, reimbursement know‑how, and tight engagement with
Banco Bradesco Stock (BBD, BBDC4) in Focus on Dec. 19, 2025: R$3.9B Shareholder Payout, 2026 JCP Calendar, Analyst Targets and Outlook

Banco Bradesco Stock (BBD, BBDC4) in Focus on Dec. 19, 2025: R$3.9B Shareholder Payout, 2026 JCP Calendar, Analyst Targets and Outlook

Banco Bradesco S.A. is closing out 2025 with a shareholder-remuneration headline that’s hard to ignore: the bank’s board approved R$3.9 billion in supplementary “interest on shareholders’ equity” (JCP)—a Brazil-specific payout mechanism that functions a lot like a dividend from an investor’s perspective, but is taxed differently. Investidor10+2Investing.com Brasil+2 For Bradesco stock investors—whether you follow BBDC4 (preferred shares) and BBDC3 (common shares) on Brazil’s B3 exchange or the NYSE-listed ADR (BBD)—today’s news is mainly about cash returns, timing, and what this says about management’s confidence heading into 2026. Investidor10+1 Below is a full, up-to-date wrap of the current news, forecasts, and
19 December 2025
Archer Aviation Stock (ACHR) on Dec. 19, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Archer Aviation Stock (ACHR) on Dec. 19, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Archer Aviation Inc. (NYSE: ACHR) is back in the spotlight on Dec. 19, 2025, as U.S. policy tailwinds collide with the company’s fast-expanding “go-to-market” map for electric air taxis. Shares traded around $7.82 in the latest available pricing, up roughly 3% from the prior close. That price action is arriving alongside a cluster of headline catalysts: Archer says it has partnered with multiple U.S. cities to apply for early air-taxi trials under a federal pilot program; the U.S. Department of Transportation (DOT) has rolled out a decade-long Advanced Air Mobility (AAM) strategy; and Archer continues to build infrastructure and regulatory
19 December 2025
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) stock was essentially flat on Friday, Dec. 19, 2025, trading around $25.04 in midday trading, after a volatile week that blended policy headlines, a reset of near-term financial expectations, and fresh pipeline updates. For investors, the story around Pfizer stock right now is less about a single headline and more about a three-way tug-of-war: Below is a roundup of the most consequential Pfizer stock news, forecasts, and analysis points investors are digesting as of 19.12.2025. Pfizer stock price today: PFE steadies near $25 as investors weigh policy and guidance As of 14:16 UTC on Dec. 19,
Ambev S.A. Stock (ABEV) on Dec. 19, 2025: Dividend Timeline, Buyback Plans, Analyst Calls, and What Comes Next

Ambev S.A. Stock (ABEV) on Dec. 19, 2025: Dividend Timeline, Buyback Plans, Analyst Calls, and What Comes Next

Ambev S.A. (NYSE: ABEV; B3: ABEV3) is back in the spotlight as December’s corporate actions collide with a shifting Brazilian tax landscape and a still-soft beverage demand backdrop. As of Dec. 19, 2025 (13:15 UTC), Ambev’s U.S.-listed shares traded around $2.48, down about 1.6% from the prior close. For investors, the story right now is not a single headline—it’s the intersection of ex-dividend timing, a major payout decision, a large share buyback authorization, capacity investments aimed at premium growth, and a market that’s increasingly sensitive to what 2026’s tax rules may do to capital returns. What’s driving Ambev stock attention
19 December 2025
Comcast Stock (CMCSA) News and Forecast on Dec. 19, 2025: Versant Spinoff Countdown, Activist Buzz, and Wall Street Price Targets

Comcast Stock (CMCSA) News and Forecast on Dec. 19, 2025: Versant Spinoff Countdown, Activist Buzz, and Wall Street Price Targets

Comcast Corporation (NASDAQ: CMCSA) heads into December 19, 2025 with its stock caught in a very Comcast-ish paradox: the business still throws off big cash, owns irreplaceable media and distribution assets, and keeps finding growth pockets (wireless, theme parks)… yet the market is treating it like a melting ice cube because broadband growth has slowed, cord-cutting hasn’t, and competition is turning pricing into a knife fight. As of the Dec. 18 close, CMCSA sat around $30.27 with pre-market indications near $30.21 early on Dec. 19, putting Comcast’s market cap around $110.3B (and roughly -33% year-over-year by market cap). StockAnalysis So
MARA Holdings (MARA) Stock News on Dec. 19, 2025: Why Shares Are Sliding, What Analysts Forecast, and the AI Data Center Pivot Investors Can’t Ignore

MARA Holdings (MARA) Stock News on Dec. 19, 2025: Why Shares Are Sliding, What Analysts Forecast, and the AI Data Center Pivot Investors Can’t Ignore

MARA Holdings, Inc. (NASDAQ: MARA) stock is limping into the final stretch of 2025 under heavy pressure, as crypto-linked equities feel every tremor in Bitcoin’s risk-on/risk-off mood swings. MARA shares traded around $9.69 in early Friday action (Dec. 19), down about 2% versus the prior close at the time of writing. Bitcoin, meanwhile, hovered near $88,120, still well below its October peak cited by Reuters—and that gap matters because MARA isn’t just “crypto-adjacent.” It’s structurally tethered to Bitcoin’s price, mining economics, and investor sentiment about the whole sector. Reuters So what’s actually moving MARA stock today—and what are the most
19 December 2025
Netflix-Warner Bros. Discovery Deal: Paramount’s Ellison-Backed Counterbid, Antitrust Pressure, and What It Means for Crave in Canada

Netflix-Warner Bros. Discovery Deal: Paramount’s Ellison-Backed Counterbid, Antitrust Pressure, and What It Means for Crave in Canada

December 19, 2025 — The battle for Warner Bros. Discovery’s crown-jewel entertainment assets just entered a more volatile phase, with a major WBD shareholder signaling it would consider a revised Paramount Skydance offer—if the bidder fixes the very financing and deal-term concerns WBD’s board has been hammering for days. Reuters At stake is far more than bragging rights in Hollywood’s consolidation era. A Netflix takeover of WBD’s studios and HBO operation would reshape the global streaming pecking order, potentially putting franchises like Harry Potter, DC, and HBO’s prestige pipeline under Netflix’s umbrella. ir.netflix.net But in Canada, the deal lands with
1 613 614 615 616 617 890

Stock Market Today

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

7 February 2026
Apple closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. The S&P 500 jumped 1.97% and the Nasdaq rose 2.18% as chipmakers rallied, while Amazon fell 5.6% on higher capex guidance. Investors await U.S. jobs data Feb. 11 and CPI Feb. 13. Apple’s next dividend is $0.26 per share, payable Feb. 12.
Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop